Abliva AB Interim Report January – September 2024
- Positive Interim Analysis of the FALCON Study Paves the Way for KL1333 Development -
Press releases
Abliva AB Interim Report January – September 2023
KL1333 Received FDA Fast Track Designation | The FALCON Study Reached an Important Milestone
Abliva AB Interim Report January – September 2022
Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases
Abliva AB Interim Report January – September 2021
Endpoint validated enables KL1333 Phase 2/3 study start ⎮ Favorable feedback supports progressing NV354 into Phase 1
Abliva AB Interim Report January – September 2020
KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021
NeuroVive Pharmaceutical AB Interim Report January – September 2019
Continued progress in KL1333.
NeuroVive Pharmaceutical AB Interim report January – September 2018
KL1333 approved for phase I clinical trial
NeuroVive Pharmaceutical AB Interim report January – September 2017
Continued positive trend for NeuroSTAT® Business operations
NeuroVive Pharmaceutical AB Interim Report January – September 2016
New business model generates opportunities
NeuroVive: Interim Report 1 Jan. 2015 to 30 Sep. 2015
Focus forward on R&D
NeuroVive: Interim Report 1 Jan. 2014 to 30 Sep. 2014
Important outlicensing deal and increased focus on core operations
NeuroVive: Interim Report 1 Jan. 2013 till 30 Sep. 2013
Increased interest in NeuroVives product portfolio with cyclophilin inhibitors and energy regulators